ELI-002 7P

May 11, 2026 — Elicio Therapeutics, Inc. (Nasdaq: ELTX) reported Q1 2026 financial results and provided clinical updates for its ongoing randomized Phase 2 AMPLIFY-7P trial of ELI-002 7P (an off-the-shelf KRAS-targeted immunotherapy) in post-resection mutant KRAS pancreatic ductal adenocarcinoma (PDAC). The event-driven primary disease-free survival (DFS) analysis is expected mid-year 2026; the company noted fewer disease progressions and deaths than projected to date, while remaining blinded to efficacy outcomes. After the primary DFS analysis, Elicio plans to request an FDA End-of-Phase 2 meeting to align on Phase 3 design and advance toward a registrational study.

Financially, Q1 2026 R&D expense was $6.8M (vs $7.8M Q1 2025), G&A was $3.8M (vs $3.0M), and net loss was $11.8M (vs $11.2M), with net loss per share of $0.65 (vs $0.87). Cash and cash equivalents were $14.9M at March 31, 2026 (vs $18.6M at year-end 2025). The company raised ~$8.0M net in Q1 and an additional ~$5.0M net in Q2-to-date via its ATM, extending projected cash runway into Q4 2026, beyond the anticipated DFS readout.